Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106923 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02106923: Completed Phase 1 study, sponsored by Boehringer Ingelheim.
NCT02106923 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02106923, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
Primary Outcome
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).
Interventions
- DRUG 1 tablet Empagliflozin/2 tablets Metformin XR
- DRUG 10 mg Empagliflozin/1000 mg Metformin XR
- DRUG 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
- DRUG 2 tablets 5 mg Empagliflozin/750 Metformin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT02106923 record still lists
NCT02106923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 4 interventions - of which 1 tablet Empagliflozin/2 tablets Metformin XR is the first listed.
NCT02106923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02106923 about?
NCT02106923 is a clinical study titled "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets". The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
What is the current status of trial NCT02106923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2014-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02106923?
The interventions under investigation include: 1 tablet Empagliflozin/2 tablets Metformin XR (DRUG), 10 mg Empagliflozin/1000 mg Metformin XR (DRUG), 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR (DRUG), 2 tablets 5 mg Empagliflozin/750 Metformin XR (DRUG).
Who is sponsoring clinical trial NCT02106923?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02106923's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia